|
|
|
Wednesday, August 27, 2008
 Latest
Anemia Medical and Health News Headlines
|
|
Anemia Medical and Health News Headlines
|
|
|
|
|
|
|
|
|
|
|
All Recent Anemia Medical Condition News Headlines |
|
|
|
|
|
|
Prospective trial of mycophenolate mofetil–cyclosporine a prophylaxis for acute gvhd after g-csf stimulated allogeneic bone marrow transplantation with hla-identical sibling donors in patients with severe aplastic anemia and hematological malignancies
Ostronoff F, Ostronoff M, Souto-Maior AP, Domingues M, Sucupira A, Manso DA, de Lima AKF, Monteiro PG, Florêncio R, Calixto R. Prospective trial of mycophenolate mofetil[ndash]cyclosporine A prophylaxis for acute GVHD after G-CSF stimulated allogeneic bone marrow transplantation with HLA-identical sibling donors in patients with severe aplastic anemia and hematological malignancies.Clin Transplant 2008 DOI:10.1111/j.1399-0012.2008.00894.x© 2008 Wiley Periodicals, Inc.Abstract: The combination of methotrexate and cyclosporine A (MTX[ndash]CSA) is the standard regimen for the prevention of graft vs. host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (allo-SCT) from HLA-identical siblings. Mycophenolate mofetil and CSA (MMF[ndash]CSA) combination has been successfully used for GVHD prophylaxis after non-reduced intensity conditioning (non-RIC) allo-SCT with peripheral blood or non-G-CSF stimulated bone marrow as stem cell source. We report the results of the first prospective trial of the MMF[ndash]CSA combination for acute GVHD prophylaxis in 47 patients after non-RIC G-CSF stimulated allo-BMT (G-BMT) from HLA-identical siblings in patients with severe aplastic anemia (SAA) or hematological malignancies. Median age was 28 yr (range, 6[ndash]48 yr). Median follow-up was 22 months. The median time to neutrophil and platelets recovery were nine d (range, 8[ndash]17) and 16 d (range, 10[ndash]28), respectively. Acute GVHD of grade II[ndash]IV and chronic GVHD occurred in 51% and 27%, respectively. Overall survival rates at two yr for patients with SAA and hematological malignancies were 87% and 65%, respectively. The event-free survival at two yr for patients with hematological malignancies was 76%. We concluded that MMF[ndash]CSA appears equivalent to MTX[ndash]CSA for GVHD prophylaxis in patients receiving non-RIC G-BMT from HLA-identical siblings, with a tendency for more rapid neutrophil engraftment. (Source: Clinical Transplantation)...
POSTED 08/24/2008 at 11:00 PM --
|
Ceftriaxone: haemolytic anaemia in an elderly patient: case report.
Page: 13 (Source: Reactions Weekly)...
POSTED 08/23/2008 at 05:12 AM --
|
Prevalence and risk factors of severe obstetric haemorrhage.
Prevalence and risk factors of severe obstetric haemorrhage.
BJOG. 2008 Sep;115(10):1265-72
Authors: Al-Zirqi I, Vangen S, Forsen L, Stray-Pedersen B
OBJECTIVE: To determine the prevalence, causes, risk factors and acute maternal complications of severe obstetric haemorrhage. DESIGN: Population-based registry study. POPULATION: All women giving birth (307,415) from 1 January 1999 to 30 April 2004 registered in the Medical Birth Registry of Norway. Information about socio-economic risk factors was obtained from Statistics Norway. METHODS: Cross-tabulation was used to study prevalence, causes and acute maternal complications of severe obstetric haemorrhage. Associations of severe obstetric haemorrhage with demographic, medical and obstetric risk factors were estimated using multiple logistic regression models. MAIN OUTCOME MEASURE: Severe obstetric haemorrhage (blood loss of > 1500 ml or blood transfusion). RESULTS: Severe obstetric haemorrhage was identified in 3501 women (1.1%). Uterine atony, retained placenta and trauma were identified causes in 30, 18 and 13.9% of women, respectively. The demographic factors of a maternal age of > or =30 years and South-East Asian ethnicity were significantly associated with an increased risk of haemorrhage. The risk was lower in women of Middle Eastern ethnicity, more than three and two times higher for emergency caesarean delivery and elective caesarean than for vaginal birth, respectively, and substantially higher for multiple pregnancies, von Willebrand's disease and anaemia (haemoglobin <9 g/dl) during pregnancy. Admissions to an intensive care unit, postpartum sepsis, hysterectomy, acute renal failure and maternal deaths were significantly more common among women with severe haemorrhage. CONCLUSION: The high prevalence of severe obstetric haemorrhage indicates the need to review labour management procedures. Demographic and medical risk factors can be managed with extra vigilance.
PMID: 18715412 [PubMed - in process] (Source: BJOG : An International Journal of Obstetrics and Gynaecology)...
POSTED 08/23/2008 at 05:00 AM --
|
Anaphylaxis to oral iron salts. desensitization protocol for tolerance induction.
Anaphylaxis to oral iron salts. desensitization protocol for tolerance induction.
J Investig Allergol Clin Immunol. 2008;18(4):305-8
Authors: de Barrio M, Fuentes V, Tornero P, Sánchez I, Zubeldia J, Herrero T
Allergies to iron salts are seldom reported. We studied a patient with iron-deficiency anemia who had suffered anaphylactic reactions caused by oral iron salts. An allergy study was performed using single-blind, placebo-controlled oral challenge and skin tests with various iron salts as well as excipients in commercial formulations. Oral challenges were positive for 2 of the commercial formulations of iron salts. Intradermal tests with ferrous sulphate and ferrous lactate also showed positive results. All of the cutaneous tests using the excipients were negative. A desensitization protocol was designed which enabled us to readminister ferrous sulphate, although antihistamines were necessary to guarantee good tolerance to iron salts. We report a patient with allergy to iron salts, positive skin tests, and positive controlled challenge. We highlight the desensitization protocol designed to complete the therapeutic management of the anemia.
PMID: 18714540 [PubMed - in process] (Source: Journal of Investigational Allergology & Clinical Immunology)...
POSTED 08/23/2008 at 03:13 AM --
|
Response to mercaptopurine for refractory autoimmune cytopenias in children
Several treatment strategies are available for children with severe immune thrombocytopenic purpura (ITP) and other immune cytopenias refractory to initial therapies. 6-Mercaptopurine (6MP) is one option, however it has not been well studied in children, especially as a single agent, and no pediatric case series have been reported since 1970.We reviewed the experience at our institution over 8 years, using 6MP as a steroid sparing treatment for children with ITP, auto-immune hemolytic anemia (AIHA) or Evans syndrome. A total of 29 pediatric patients were treated with 6MP from 2000 to 2007.Response was defined as a rise in hemoglobin by at least 1.5 g/dl and to a level of 10 g/dl or greater in patients treated for anemia, or a platelet count [ge]50 × 109/L in patients treated for thrombocytopenia. We found an overall response rate of 83% among all patients. Fourteen percent of patients stopped drug because of side effects.These results suggest that 6MP can be an effective single-agent treatment for refractory immune cytopenias in children. Prospective studies are warranted to determine long-term efficacy and toxicity and to more clearly define patient populations most likely to respond. Pediatr Blood Cancer © 2008 Wiley-Liss, Inc. (Source: Pediatric Blood and Cancer)...
POSTED 08/22/2008 at 11:00 PM --
|
Breast calcification on screening mammography
A 42-year-old Nigerian woman living in the UK presents for a mammography. While her physical exam is generally normal, her lab exam reveals microcytic anemia, BUN of 56 mg/dL, and creatinine of 6.2 mg/dL. The mammogram is obtained. What is the underlying etiology? eMedicine Case Presentations (Source: Medscape PublicHealth Headlines)...
POSTED 08/22/2008 at 09:05 PM --
|
Unusual warm autoimmune hemolytic anemia in non-alcoholic steatohepatitis.
Unusual warm autoimmune hemolytic anemia in non-alcoholic steatohepatitis.
Ann Clin Lab Sci. 2008;38(3):273-6
Authors: Boctor FN, Gorak E, Prichard JW, Firouzi M, Difilippo W
Warm autoimmune hemolytic anemia (WAIHA), a rare disease (0.2-1 per 100,000 population), ranges from an indolent form with mild hemolysis to a life-threatening condition that necessitates transfusion of incompatible red cells. WAIHA can be either idiopathic or secondary to medications or to a lymphoproliferative disorder. We report a case of profound hemolytic anemia in a liver-transplant eligible patient who was diagnosed with cirrhosis secondary to non-alcoholic steatohepatitis (NASH). The patient initially was treated with red cell transfusion, iv immunoglobulin, and steroids. He developed acute renal failure that required dialysis. Subsequent management included plasmapheresis and rituximab therapy. The patient developed hepatorenal syndrome and died from progressive hepatic failure. To our knowledge, this is the first report of an association between NASH and WAIHA.
PMID: 18715857 [PubMed - in process] (Source: Annals of Clinical and Laboratory Science)...
POSTED 08/22/2008 at 09:25 AM --
|
Fda approves vidaza label expansion
The Aplastic Anemia & MDS International Foundation (AA&MDSIF) is pleased to inform patients that the U.S. Food & Drug Administration (FDA) has expanded the label for VIDAZA (azacitidine) to include data from the AZA-001 trial, which found that Vidaza is the only agent that extends survival in MDS (myelodysplastic syndromes) patients. (Source: Health News from Medical News Today)...
POSTED 08/22/2008 at 05:00 AM --
|
Simultaneous bladder and vaginal reconstruction using ileum in complicated vesicovaginal fistula
Patwardhan Sujata K, Sawant Ajit, Ismail Mohammad, Nagabhushana M, Varma Radheshyam RIndian Journal of Urology 2008 24(3):348-351<b>Objectives:</b> To discuss the outcome of surgical repair in complicated vesicovaginal fistula with simultaneous bladder and vaginal reconstruction using ileum.
<b> Materials and Methods:</b> Four female patients in the age group of 12-30 years are included. All the patients had complicated vesicovaginal fistula with vaginal stenosis secondary to obstetric hysterectomy (except one secondary to the genitourinary tuberculosis). Repair of vesicovaginal fistula with simultaneous bladder augmentation, ureteric reimplantation, and reconstruction of vagina using ileum was performed in all the cases.
<b> Results:</b> All the patients had successful repair of fistula. Vaginal reconstruction using ileum, resulted in capacious vagina. Adult patients resumed to normal sexual life. Mucus discharge was the only complaint in postoperative period.
<b> Conclusions:</b> Malnutrition, anemia, obstructed labor, Intra uterine fetal death (IUFD), postpartum hemorrhage following forceps delivery in a rural setting followed by an emergency obstetric hysterectomy after a delay of 6-8 h (due to transfer to a tertiary center) were the few contributing factors leading to the formation of vesicovaginal fistula (VVF). Preoperative assessment of bladder capacity and vaginal capacity in such cases is mandatory. The small bowel is a readily available vascular tissue for restoring bladder and vaginal capacity. (Source: Indian Journal of Urology)...
POSTED 08/22/2008 at 04:31 AM --
|
Tri-lineage disease involving sideroblastic anaemia, multiple myeloma and b-cell non-hodgkin’s lymphoma in the same patient
Tri-lineage disease involving sideroblastic anaemia, multiple myeloma and B-cell non-Hodgkin’s lymphoma in the same patient
Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-008-0586-5Authors
Jean-Christophe Ianotto, Hôpital Morvan Institut de cancéro-hématologie, Département d’Hématologie CHU Brest FranceAdrian Tempescul, Hôpital Morvan Institut de cancéro-hématologie, Département d’Hématologie CHU Brest FranceJean-Richard Eveillard, Hôpital Morvan Institut de cancéro-hématologie, Département d’Hématologie CHU Brest FranceVéronique Marion, Hôpital Morvan Laboratoire d’hématologie CHU Brest FranceIsabelle Quintin-Roué, Hôpital Morvan Laboratoire d’anatomopathologie CHU Brest FranceChristian Berthou, Hôpital Morvan Institut de cancéro-hématologie, Département d’Hématologie CHU Brest France
Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555 (Source: Annals of Hematology)...
POSTED 08/22/2008 at 04:08 AM --
|
Adding fresh frozen plasma to rituximab for the treatment of patients with refractory advanced cll
Background: Many patients with chronic lymphocytic leukaemia (CLL) develop progressive, treatment-resistant disease. Rituximab (RTX), a monoclonal antibody targeting CD20 on B lymphocytes and widely used in other indolent B cell neoplasms is less efficacious in CLL, possibly due to associated complement deficiencies.
Objective: To examine in open trial whether providing complement by concurrent administration of fresh frozen plasma (FFP) will enhance the effect of RTX in CLL.
Setting: Outpatient haematology clinics in Israel and Greece.
Patients: Five patients with severe treatment-resistant CLL. All had been previously treated with fludarabine and three also failed treatment with RTX.
Intervention: Two units of FFP followed with RTX 375 mg/m2 as a single agent, repeated every 1–2 weeks, as needed.
Results: A rapid and dramatic clinical and laboratory response was achieved in all patients. Lymphocyte counts dropped markedly followed by shrinkage of lymph nodes and spleen and improvement of the anaemia and thrombocytopenia. This could be maintained over 8 months (median) with additional cycles if necessary. Treatment was well tolerated in all cases.
Conclusion: Adding FFP to RTX may provide a useful therapeutic option in patients with advanced CLL resistant to treatment. (Source: QJM)...
POSTED 08/21/2008 at 11:00 PM --
|
Anaemia as predictor of gastrointestinal bleeding in atrial fibrillation patients undergoing percutaneous coronary artery stenting
(Source: QJM)...
POSTED 08/21/2008 at 11:00 PM --
|
Association between wind speed and the occurrence of sickle cell acute painful episodes: results of a case-crossover study
The role of the weather as a trigger of sickle cell acute painful episodes has long been debated. To more accurately describe the role of the weather as a trigger of painful events, we conducted a case-crossover study of the association between local weather conditions and the occurrence of painful episodes. From the Cooperative Study of Sickle Cell Disease, we identified 813 patients with sickle cell anaemia who had 3570 acute painful episodes. We found an association between wind speed and the onset of pain, specifically wind speed during the 24-h period preceding the onset of pain. Analysing wind speed as a categorical trait, showed a 13% increase (95% confidence interval: 3%, 24%) in odds of pain, when comparing the high wind speed to lower wind speed (P = 0·007). In addition, the association between wind speed and painful episodes was found to be stronger among men, particularly those in the warmer climate regions of the United States. These results are in agreement with another study that found an association between wind speed and hospital visits for pain in the United Kingdom, and lends support to physiological and clinical studies that have suggested that skin cooling is associated with sickle vasoocclusion and perhaps pain. (Source: British Journal of Haematology)...
POSTED 08/21/2008 at 11:00 PM --
|
Host control of malaria infections: constraints on immune and erythropoeitic response kinetics
by Philip G. McQueen, F. Ellis McKenzie
Author Summary
Of the four Plasmodium species that parasitize human erythrocytes and induce malaria, Plasmodium falciparum and Plasmodium vivax cause most of the public health burden. P. falciparum infection is typically characterized as “malignant” (due to severe, sometimes lethal consequences, particularly in immune-naïve individuals), and P. vivax malaria as (relatively) “benign.” Using the power of a Beowulf cluster, we tested hypotheses about host control of malaria by simulating ~8.4×104 combinations of parasite species, host immune response, and erythropoietic response to infection. We tailored the models to specific details of the life cycles of the two species, which invade different subclasses of red blood cells. Our results challenge some standard assumptions. For example, we show that tight synchronization of the asexual reproduction of malaria parasites may actually benefit the host by reducing parasitemia. We also demonstrate that properties of host immunity or erythropoiesis that contribute to high parasitemia and severe anemia in P. falciparum malaria would do so in P. vivax infection as well, in line with recent reports indicating that P. vivax can indeed cause “malignant” illness in some patients. This suggests that P. falciparum is more effective overall at immune evasion or suppression than P. vivax. (Source: PLoS Computational Biology)...
POSTED 08/21/2008 at 11:00 PM --
|
Relative red blood cell enzyme levels as a clue to the diagnosis of pyruvate kinase deficiency
Evaluation of two patients with transfusion dependent anemia revealed RBC pyruvate kinase to be 33% and 41% of the mean normal value, with normal or high values of other RBC enzymes. Parental PK activities were just below normal in three of four of the parents. Subsequent DNA analysis revealed both patients to be compound heterozygotes for PKLR gene mutations, two of which are previously undescribed. Borderline low pyruvate kinase activities with increased in other RBC enzyme activities should prompt consideration of measurement of parental enzyme activities, and confirmation by DNA analysis if available. Pediatr Blood Cancer © 2008 Wiley-Liss, Inc. (Source: Pediatric Blood and Cancer)...
POSTED 08/21/2008 at 11:00 PM --
|
Hemolytic disease of the fetus and newborn due to anti-ge3: combined antibody-dependent hemolysis and erythroid precursor cell growth inhibition
Amer J PerinatolDOI: 10.1055/s-0028-1085072ABSTRACTThe Gerbich (Ge) antigens are a collection of high-incidence antigens carried on the red blood cell membrane glycoproteins, glycophorins C and D. Antibodies against these antigens are uncommon, and there have been only rare case reports of hemolytic disease of the fetus and newborn due to anti-Ge. In this case report, we present a neonate with severe anemia and hyperbilirubinemia due to anti-Ge3. Routine and special laboratory studies undertaken in this case suggested two mechanisms for the patient's hemolysis and persistent anemia. Antibody-dependent hemolysis was associated with early-onset hyperbilirubinemia, anemia, and a mild reticulocytosis, and inhibition of erythroid progenitor cell growth was associated with late anemia and normal bilirubin and reticulocyte values. Though rare, anti-Ge3 can be a dangerous antibody in pregnancy. Affected neonates may require intensive initial therapy and close follow-up for at least several weeks after delivery.[...]© Thieme Medical PublishersGet connected:Table of contents | Abstract | Full text (Source: American Journal of Perinatology)...
POSTED 08/21/2008 at 07:40 PM --
|
Unusual lymphocytosis with systemic lupus erythematosus
Abstract A 15-year-old boy with systemic lupus erythematosus, who on a follow up visit complained of recurrent episodes of fever, easy
fatiguability, and seizures. Investigations revealed lymphocytosis (95%), anemia, and a positive PCR for cytomegalovirus (CMV).
Electron microscopy of the lymphocytes revealed intranuclear inclusion bodies supporting the diagnosis of CMV infection. The
child was treated with ganciclovir and discharged. At discharge the child was afebrile. However, lymphocytosis persisted even
after 9 months of discharge. Repeated screening for possible lymphoreticular malignancy was negative. It is likely that lymphocytosis
in this child was due to persistence of CMV infection in host cells leading to continued provocation of the host immune system.
Content Type Journal ArticleCategory Clinical BriefDOI 10.1007/s12098-008-0142-2Authors
Jhuma Sankar, All India Institute of Medical Sciences Department of Pediatrics Ansari Nagar New Delhi IndiaRakesh Lodha, All India Institute of Medical Sciences Department of Pediatrics Ansari Nagar New Delhi IndiaM. Jeeva Sankar, All India Institute of Medical Sciences Department of Pediatrics Ansari Nagar New Delhi IndiaDevendra Kumar Mitra, All India Institute of Medical Sciences Department Transplant Immunology and Immunogenetics Ansari Nagar New Delhi IndiaRajive Kumar, All India Institute of Medical Sciences Department Laboratory Oncology Ansari Nagar New Delhi IndiaSushil Kumar Kabra, All India Institute of Medical Sciences Department of Pediatrics Ansari Nagar New Delhi India
Journal Indian Journal of PediatricsOnline ISSN 0973-7693Print ISSN 0019-5456
Journal Volume Volume 75
Journal Issue Volume 75, Number 7 / July, 2008 (Source: Indian Journal of Pediatrics)...
POSTED 08/21/2008 at 06:48 AM --
|
Current trends in the management of beta thalassemia
Abstract The management of Beta Thalassemia, the commonest form of hemolytic anemia in children, has changed significantly in the last
few years. With the availability of better transfusion regimen, iron chelation therapy, proper management of complications
and good supportive care, it is now possible for a thalassemic child to have a near normal life span with a good quality of
life.
Content Type Journal ArticleCategory Symposium on Advances in HematologyDOI 10.1007/s12098-008-0140-4Authors
A. P. Dubey, Maulana Azad Medical College and Lok Nayak Hospital Department of Pediatrics New Delhi IndiaA. Parakh, Maulana Azad Medical College and Lok Nayak Hospital Department of Pediatrics New Delhi IndiaS. Dublish, Maulana Azad Medical College and Lok Nayak Hospital Department of Pediatrics New Delhi India
Journal Indian Journal of PediatricsOnline ISSN 0973-7693Print ISSN 0019-5456
Journal Volume Volume 75
Journal Issue Volume 75, Number 7 / July, 2008 (Source: Indian Journal of Pediatrics)...
POSTED 08/21/2008 at 06:48 AM --
|
Correlation of thyroid and growth hormones to chromosomal instability in egyptian fanconi anemia patients
Abstract
Objective Fanconi anemia (FA) is a rare inherited genomic instability syndrome and usually associated with endocrine dysfunctions. We
aimed to assess the diagnostic standards of chromosomal instability in FA and to correlate the breakage frequency with the
severity of endocrinal dysfunctions.
Methods Twenty seven FA patients were randomly selected from Hematology Unit of Mansoura University Children’s Hospital; their mean
age 8.8 yr. Sixteen normal children matched for age and sex were used as controls. Cytogenetic studies included peripheral
blood lymphocyte cultures using phytohemagglutinin to obtain chromosomal spreads. Chromosomal breakage was induced by (i)
Diepoxybutane 0.1 μg/ml. (ii) Mitomycin C 0.1 μg/ml. (iii) Irradiation of cultures to four radiation doses; 75, 150, 300 and
400 rads (rad1, rad2, rad3 and rad4 respectively). Chromosomal aberrations were scored from the previous 6 cultures besides
a culture for spontaneous chromosomal breakage; then mean chromosomal breakage was calculated for the seven cultures. Endocrinal
evaluation included quantitative determination of thyroid stimulating hormone (TSH) and tetraiodothyronine (T4), serum growth
hormone (GH), insulin like growth factor-1 (IGF-1) and insulin levels.
Results Chromosomal breakage was found to be significantly higher in patients than control when induced by Diepoxybutane (p = 0.003),
Mitomycin (p = 0.001), rad3 (p = 0.043) and rad4 (p = 0.001). Mean chromosomal breakage was significantly negative correlated
to head circumference (r = −0.57) and GH level (r = −0.50), with no significant correlation to other hormonal parameters.
Mitomycin and rad4 were found more accurate than DEB test for diagnosis of FA in suspected cases.
Conclusion Correction of the frequently associated hormonal dysfunction (reduced GH and T4) should be considered in the treatment discipline
of FA patients to improve their final height.
Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s12098-008-0128-0Authors
Mohammad Al-Haggar, Mansoura University Department of Pediatrics and Clinical Pathology Mansoura EgyptZakaria Al-Morsy, Mansoura University Department of Pediatrics and Clinical Pathology Mansoura EgyptSohier Yahia, Mansoura University Department of Pediatrics and Clinical Pathology Mansoura EgyptNehad Chalaby, Mansoura University Department of Pediatrics and Clinical Pathology Mansoura EgyptAmany Ragab, Mansoura University Department of Pediatrics and Clinical Pathology Mansoura EgyptAbeer Mesbah, Mansoura University Faculty of Medicine Mansoura Egypt
Journal Indian Journal of PediatricsOnline ISSN 0973-7693Print ISSN 0019-5456
Journal Volume Volume 75
Journal Issue Volume 75, Number 7 / July, 2008 (Source: Indian Journal of Pediatrics)...
POSTED 08/21/2008 at 06:48 AM --
|
Phase i dose finding study evaluating the combination of bendamustine with weekly paclitaxel in patients with pre-treated metastatic breast cancer: rita trial
Abstract
Purpose The aim of the RiTa trial is to establish a feasible combination of bendamustine and paclitaxel in a weekly schedule in anthracycline
pre-treated metastatic breast cancer patients.
Methods Starting dose of bendamustine was 50 mg/m² and was stepwise increased by 10 mg/m² up to 70 mg/m². The starting dose of paclitaxel
was 60 mg/m² and was increased up to 90 mg/m². There are five pre-defined dose levels with three patients per dose level (maximum
six patients) and six patients in the last dose level according to the Goodman design. Dose-limiting toxicities were defined
as severe neutropenia and thrombocytopenia as well as non-haematological toxicities ≥NCI-CTC grade 3 in the first cycle.
Results No dose-limiting toxicity up to 70 mg/m² bendamustine and 90 mg/m2 paclitaxel occurred during the first cycle. Over all cycles, the following severe haematological toxicities (grade 3 and
4) were documented: neutropenia five patients and anaemia one patient. Relevant grade 3 and 4 non-haematological toxicities
over all cycles were fatigue two patients, dyspnoea one patient, infection four patients and bone pain in one patient. Five
serious adverse events, but no therapy related death occurred. Five patients showed a complete or partial remission, six patients
stable disease and six progressed during treatment. The median progression-free survival was 8 months.
Conclusion Treatment with weekly bendamustine and paclitaxel is a feasible and effective regimen in patients with metastatic breast cancer.
The recommended dose for forthcoming phase II study is 70 mg/m2 bendamustine and 90 mg/m2 paclitaxel.
Content Type Journal ArticleCategory Clinical Trial ReportDOI 10.1007/s00280-008-0821-8Authors
Sibylle Loibl, German Breast Group, GBG-Forschungs GmbH Schleussnerstrasse 42 63263 Neu-Isenburg GermanyCaroline Murmann, German Breast Group, GBG-Forschungs GmbH Schleussnerstrasse 42 63263 Neu-Isenburg GermanyKatrin Schwedler, J. W. Goethe University Department of Gynaecology and Obstetrics Frankfurt GermanyMathias Warm, University Hospital Department of Obstetrics and Gynaecology Cologne GermanyLothar Müller, Center for Hematology and Oncology Leer, Emden GermanyGeorg Heinrich, Outpatient Clinic for Gynaecological Oncology Fürstenwalde GermanyValentina Nekljudova, German Breast Group, GBG-Forschungs GmbH Schleussnerstrasse 42 63263 Neu-Isenburg GermanyGunter von Minckwitz, German Breast Group, GBG-Forschungs GmbH Schleussnerstrasse 42 63263 Neu-Isenburg Germany
Journal Cancer Chemotherapy and PharmacologyOnline ISSN 1432-0843Print ISSN 0344-5704 (Source: Cancer Chemotherapy and Pharmacology)...
POSTED 08/21/2008 at 04:30 AM --
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
IMPORTANT NOTICE:
The information provided on this site is intended for your general knowledge only and is not a substitute for professional
medical advice or treatment for specific medical conditions. You should not use this information to diagnose or treat a health problem or disease without consulting with a
qualified healthcare provider. Please consult your healthcare provider with any questions or concerns you may have regarding your condition.
|
|
|
|
|
|
|
|
